ART6043 is a polymerase theta inhibitor and this year at ESMO data were presented on this drug either as monotherapy or in combination with olaparib. I think that the study was very very interesting about the preliminary results because this kind of combination was very well tolerated with no signs of cumulative incidence of adverse events over monotherapy and also in terms of efficacy we clearly see some prolonged responses in patients that were deemed to be sensitive to PARP inhibition but probably there are some subgroup of patients that may derive benefit from the addition of a polymerase theta inhibitor over PARP inhibitor...
ART6043 is a polymerase theta inhibitor and this year at ESMO data were presented on this drug either as monotherapy or in combination with olaparib. I think that the study was very very interesting about the preliminary results because this kind of combination was very well tolerated with no signs of cumulative incidence of adverse events over monotherapy and also in terms of efficacy we clearly see some prolonged responses in patients that were deemed to be sensitive to PARP inhibition but probably there are some subgroup of patients that may derive benefit from the addition of a polymerase theta inhibitor over PARP inhibitor. Most importantly, looking at the efficacy, we have also observed that some patients that were probably ones we cannot expect a real benefit from PARP inhibition derive some benefit from the combination and this sets a challenge for us that we should probably study better the genomics of this tumor to identify a subgroup of patients where the combination of polymerase theta inhibitors and PARP inhibitors can be delivered in further lines of development. But in any case, I think that this data encourages this kind of combination and I guess that we will see additional data in the next international meetings.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
